Wall Street analysts expect Kitov Pharma (NASDAQ:KTOV) to announce earnings per share (EPS) of ($0.01) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kitov Pharma’s earnings. The firm is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Kitov Pharma will report full year earnings of ($0.01) per share for the current fiscal year. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Kitov Pharma.
Separately, ValuEngine downgraded Kitov Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st.
ILLEGAL ACTIVITY NOTICE: “-$0.01 Earnings Per Share Expected for Kitov Pharma (KTOV) This Quarter” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3342620/0-01-earnings-per-share-expected-for-kitov-pharma-ktov-this-quarter.html.
About Kitov Pharma
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharma and related companies with MarketBeat.com's FREE daily email newsletter.